Healthcare Utilization and Costs after Receiving a Positive BRCA1/2 Result from a Genomic Screening Program
- Supplementary File 1:
PDF-Document (PDF, 69 KiB)
Hao, J.; Hassen, D.; Manickam, K.; Murray, M.F.; Hartzel, D.N.; Hu, Y.; Liu, K.; Rahm, A.K.; Williams, M.S.; Lazzeri, A.; Buchanan, A.; Sturm, A.; Snyder, S.R. Healthcare Utilization and Costs after Receiving a Positive BRCA1/2 Result from a Genomic Screening Program. J. Pers. Med. 2020, 10, 7. https://doi.org/10.3390/jpm10010007
Hao J, Hassen D, Manickam K, Murray MF, Hartzel DN, Hu Y, Liu K, Rahm AK, Williams MS, Lazzeri A, Buchanan A, Sturm A, Snyder SR. Healthcare Utilization and Costs after Receiving a Positive BRCA1/2 Result from a Genomic Screening Program. Journal of Personalized Medicine. 2020; 10(1):7. https://doi.org/10.3390/jpm10010007
Chicago/Turabian StyleHao, Jing, Dina Hassen, Kandamurugu Manickam, Michael F. Murray, Dustin N. Hartzel, Yirui Hu, Kunpeng Liu, Alanna Kulchak Rahm, Marc S. Williams, Amanda Lazzeri, Adam Buchanan, Amy Sturm, and Susan R. Snyder. 2020. "Healthcare Utilization and Costs after Receiving a Positive BRCA1/2 Result from a Genomic Screening Program" Journal of Personalized Medicine 10, no. 1: 7. https://doi.org/10.3390/jpm10010007